NCT00216112 - Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

October 31, 2005

Study Completion Date

July 31, 2007

Conditions

Ovarian Cancer

Interventions

DRUG

Imatinib Mesylate

Imatinib mesylate 600 mg po qd

DRUG

Docetaxel

Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks

Trial Locations (9)

Indiana University Cancer Center, Indianapolis

Elkhart Clinic, Elkhart

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

Center for Cancer Care, Inc., P.C., New Albany

Medical Consultants, P.C., Muncie

Oncology Hematology Associates of SW Indiana, Evansville

AP&S Clinic, Terre Haute

Arnett Cancer Care, Lafayette

Medical & Surgical Specialists, LLC, Galesburg